Gene therapy approaches in urologic oncology.

J. Vieweg, Eli Gilboa

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The tools and concepts of cytokine gene-based immunotherapy are being applied to the development of potentially effective new adjuvant treatment modalities for urologic malignancies. In preclinical models for the most prevalent urologic cancers, such as renal cell, bladder, and prostate carcinoma, it was shown that cytokine secreting, growth inactivated, tumor cell preparations (1) are capable of inducing a T-cell response against even nonimmunogenic tumors, (2) have considerable therapeutic benefit in tumor bearing animals, and (3) establish effective immunologic memory in cured animals. These studies have advanced further our understanding of the efficacy and therapeutic use of cytokine secreting tumor cells and form the rationale for translating these preclinical results into a clinical setting. It is realistic to speculate that in the foreseeable future alternative or complementary approaches to cytokine gene-based immunotherapy will be developed that would augment immune responses in cancer patients. Genetically modified dendritic cells transduced with genes encoding isolated tumor rejection antigens or costimulatory signals, such as B7, may be even more potent immune stimulators to induce systemic immune responses. Although animal studies have shown considerable promise and investigational clinical trials are underway, additional research and further development still is required to realize the full benefit of this approach, and some forms of cancer eventually may respond to this form of cancer immunotherapy.

Original languageEnglish
Pages (from-to)203-218
Number of pages16
JournalSurgical Oncology Clinics of North America
Volume4
Issue number2
StatePublished - Apr 1 1995
Externally publishedYes

Fingerprint

Genetic Therapy
Neoplasms
Immunotherapy
Cytokines
Urologic Neoplasms
Immunologic Memory
Genes
Neoplasm Antigens
Therapeutic Uses
Dendritic Cells
Prostate
Urinary Bladder
Clinical Trials
Carcinoma
T-Lymphocytes
Kidney
Therapeutics
Growth
Research

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Gene therapy approaches in urologic oncology. / Vieweg, J.; Gilboa, Eli.

In: Surgical Oncology Clinics of North America, Vol. 4, No. 2, 01.04.1995, p. 203-218.

Research output: Contribution to journalArticle

@article{651c771664c24700bb1fde6e069d43d0,
title = "Gene therapy approaches in urologic oncology.",
abstract = "The tools and concepts of cytokine gene-based immunotherapy are being applied to the development of potentially effective new adjuvant treatment modalities for urologic malignancies. In preclinical models for the most prevalent urologic cancers, such as renal cell, bladder, and prostate carcinoma, it was shown that cytokine secreting, growth inactivated, tumor cell preparations (1) are capable of inducing a T-cell response against even nonimmunogenic tumors, (2) have considerable therapeutic benefit in tumor bearing animals, and (3) establish effective immunologic memory in cured animals. These studies have advanced further our understanding of the efficacy and therapeutic use of cytokine secreting tumor cells and form the rationale for translating these preclinical results into a clinical setting. It is realistic to speculate that in the foreseeable future alternative or complementary approaches to cytokine gene-based immunotherapy will be developed that would augment immune responses in cancer patients. Genetically modified dendritic cells transduced with genes encoding isolated tumor rejection antigens or costimulatory signals, such as B7, may be even more potent immune stimulators to induce systemic immune responses. Although animal studies have shown considerable promise and investigational clinical trials are underway, additional research and further development still is required to realize the full benefit of this approach, and some forms of cancer eventually may respond to this form of cancer immunotherapy.",
author = "J. Vieweg and Eli Gilboa",
year = "1995",
month = "4",
day = "1",
language = "English",
volume = "4",
pages = "203--218",
journal = "Surgical Oncology Clinics of North America",
issn = "1055-3207",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Gene therapy approaches in urologic oncology.

AU - Vieweg, J.

AU - Gilboa, Eli

PY - 1995/4/1

Y1 - 1995/4/1

N2 - The tools and concepts of cytokine gene-based immunotherapy are being applied to the development of potentially effective new adjuvant treatment modalities for urologic malignancies. In preclinical models for the most prevalent urologic cancers, such as renal cell, bladder, and prostate carcinoma, it was shown that cytokine secreting, growth inactivated, tumor cell preparations (1) are capable of inducing a T-cell response against even nonimmunogenic tumors, (2) have considerable therapeutic benefit in tumor bearing animals, and (3) establish effective immunologic memory in cured animals. These studies have advanced further our understanding of the efficacy and therapeutic use of cytokine secreting tumor cells and form the rationale for translating these preclinical results into a clinical setting. It is realistic to speculate that in the foreseeable future alternative or complementary approaches to cytokine gene-based immunotherapy will be developed that would augment immune responses in cancer patients. Genetically modified dendritic cells transduced with genes encoding isolated tumor rejection antigens or costimulatory signals, such as B7, may be even more potent immune stimulators to induce systemic immune responses. Although animal studies have shown considerable promise and investigational clinical trials are underway, additional research and further development still is required to realize the full benefit of this approach, and some forms of cancer eventually may respond to this form of cancer immunotherapy.

AB - The tools and concepts of cytokine gene-based immunotherapy are being applied to the development of potentially effective new adjuvant treatment modalities for urologic malignancies. In preclinical models for the most prevalent urologic cancers, such as renal cell, bladder, and prostate carcinoma, it was shown that cytokine secreting, growth inactivated, tumor cell preparations (1) are capable of inducing a T-cell response against even nonimmunogenic tumors, (2) have considerable therapeutic benefit in tumor bearing animals, and (3) establish effective immunologic memory in cured animals. These studies have advanced further our understanding of the efficacy and therapeutic use of cytokine secreting tumor cells and form the rationale for translating these preclinical results into a clinical setting. It is realistic to speculate that in the foreseeable future alternative or complementary approaches to cytokine gene-based immunotherapy will be developed that would augment immune responses in cancer patients. Genetically modified dendritic cells transduced with genes encoding isolated tumor rejection antigens or costimulatory signals, such as B7, may be even more potent immune stimulators to induce systemic immune responses. Although animal studies have shown considerable promise and investigational clinical trials are underway, additional research and further development still is required to realize the full benefit of this approach, and some forms of cancer eventually may respond to this form of cancer immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0029286101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029286101&partnerID=8YFLogxK

M3 - Article

C2 - 7796281

AN - SCOPUS:0029286101

VL - 4

SP - 203

EP - 218

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

SN - 1055-3207

IS - 2

ER -